Mechanisms of Taxol resistance related to microtubules

George A. Orr, Pascal Verdier-Pinard, Hayley M. McDaid, Susan Band Horwitz

Research output: Contribution to journalArticle

472 Citations (Scopus)

Abstract

Since its approval by the FDA in 1992 for the treatment of ovarian cancer, the use of Taxol has dramatically increased. Although treatment with Taxol has led to improvement in the duration and quality of life for some cancer patients, the majority eventually develop progressive disease after initially responding to Taxol treatment. Drug resistance represents a major obstacle to improving the overall response and survival of cancer patients. This review focuses on mechanisms of Taxol resistance that occur directly at the microtubule, such as mutations, tubulin isotype selection and post-translational modifications, and also at the level of regulatory proteins. A review of tubulin structure, microtubule dynamics, the mechanism of action of Taxol and its binding site on the microtubule are included, so that the reader can evaluate Taxol resistance in context.

Original languageEnglish (US)
Pages (from-to)7280-7295
Number of pages16
JournalOncogene
Volume22
Issue number47 REV. ISS. 6
DOIs
StatePublished - Oct 20 2003

Fingerprint

Paclitaxel
Microtubules
Tubulin
Post Translational Protein Processing
Drug Resistance
Ovarian Neoplasms
Neoplasms
Therapeutics
Binding Sites
Quality of Life
Mutation
Survival
Proteins

Keywords

  • Microtubule
  • Resistance
  • Taxol

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics

Cite this

Mechanisms of Taxol resistance related to microtubules. / Orr, George A.; Verdier-Pinard, Pascal; McDaid, Hayley M.; Band Horwitz, Susan.

In: Oncogene, Vol. 22, No. 47 REV. ISS. 6, 20.10.2003, p. 7280-7295.

Research output: Contribution to journalArticle

Orr, George A. ; Verdier-Pinard, Pascal ; McDaid, Hayley M. ; Band Horwitz, Susan. / Mechanisms of Taxol resistance related to microtubules. In: Oncogene. 2003 ; Vol. 22, No. 47 REV. ISS. 6. pp. 7280-7295.
@article{fd7c774779b048f18eeb46dd03102d02,
title = "Mechanisms of Taxol resistance related to microtubules",
abstract = "Since its approval by the FDA in 1992 for the treatment of ovarian cancer, the use of Taxol has dramatically increased. Although treatment with Taxol has led to improvement in the duration and quality of life for some cancer patients, the majority eventually develop progressive disease after initially responding to Taxol treatment. Drug resistance represents a major obstacle to improving the overall response and survival of cancer patients. This review focuses on mechanisms of Taxol resistance that occur directly at the microtubule, such as mutations, tubulin isotype selection and post-translational modifications, and also at the level of regulatory proteins. A review of tubulin structure, microtubule dynamics, the mechanism of action of Taxol and its binding site on the microtubule are included, so that the reader can evaluate Taxol resistance in context.",
keywords = "Microtubule, Resistance, Taxol",
author = "Orr, {George A.} and Pascal Verdier-Pinard and McDaid, {Hayley M.} and {Band Horwitz}, Susan",
year = "2003",
month = "10",
day = "20",
doi = "10.1038/sj.onc.1206934",
language = "English (US)",
volume = "22",
pages = "7280--7295",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "47 REV. ISS. 6",

}

TY - JOUR

T1 - Mechanisms of Taxol resistance related to microtubules

AU - Orr, George A.

AU - Verdier-Pinard, Pascal

AU - McDaid, Hayley M.

AU - Band Horwitz, Susan

PY - 2003/10/20

Y1 - 2003/10/20

N2 - Since its approval by the FDA in 1992 for the treatment of ovarian cancer, the use of Taxol has dramatically increased. Although treatment with Taxol has led to improvement in the duration and quality of life for some cancer patients, the majority eventually develop progressive disease after initially responding to Taxol treatment. Drug resistance represents a major obstacle to improving the overall response and survival of cancer patients. This review focuses on mechanisms of Taxol resistance that occur directly at the microtubule, such as mutations, tubulin isotype selection and post-translational modifications, and also at the level of regulatory proteins. A review of tubulin structure, microtubule dynamics, the mechanism of action of Taxol and its binding site on the microtubule are included, so that the reader can evaluate Taxol resistance in context.

AB - Since its approval by the FDA in 1992 for the treatment of ovarian cancer, the use of Taxol has dramatically increased. Although treatment with Taxol has led to improvement in the duration and quality of life for some cancer patients, the majority eventually develop progressive disease after initially responding to Taxol treatment. Drug resistance represents a major obstacle to improving the overall response and survival of cancer patients. This review focuses on mechanisms of Taxol resistance that occur directly at the microtubule, such as mutations, tubulin isotype selection and post-translational modifications, and also at the level of regulatory proteins. A review of tubulin structure, microtubule dynamics, the mechanism of action of Taxol and its binding site on the microtubule are included, so that the reader can evaluate Taxol resistance in context.

KW - Microtubule

KW - Resistance

KW - Taxol

UR - http://www.scopus.com/inward/record.url?scp=0345688612&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0345688612&partnerID=8YFLogxK

U2 - 10.1038/sj.onc.1206934

DO - 10.1038/sj.onc.1206934

M3 - Article

VL - 22

SP - 7280

EP - 7295

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 47 REV. ISS. 6

ER -